{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T08:12:46Z","timestamp":1769760766549,"version":"3.49.0"},"reference-count":17,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,7,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Autologous stem cell transplantation (ASCT) followed by lenalidomide maintenance therapy is the standard of care for transplant-eligible patients with newly diagnosed multiple myeloma (NDMM). Clinical trials show progression-free survival (PFS) benefits, with some studies (Cancer and Leukemia Group [CALGB] trial and meta-analysis) also showing overall survival (OS) benefits, but applicability to real-world clinical settings is unclear. Using data from Connect MM, the largest US-based observational registry of NDMM patients, we analyzed effects of maintenance therapy on long-term outcomes in 1450 treated patients enrolled from 2009 to 2011. Patients who received induction therapy and ASCT (n = 432) were analyzed from 100 days post-ASCT (data cut 7 January 2016): 267 received maintenance (80% lenalidomide-based [of whom 88% received lenalidomide monotherapy]); 165 did not. Lenalidomide maintenance improved median PFS and 3-year PFS rate vs no maintenance (50.3 vs 30.8 months [hazard ratio (HR), 0.62; 95% confidence interval (CI), 0.46-0.82; P &amp;lt; .001] and 56% vs 42%, respectively). Improvements in median OS and 3-year OS rate were associated with lenalidomide maintenance vs no maintenance (not reached in either group [HR, 0.54; 95% CI, 0.36-0.83; P = .005] and 85% vs 70%, respectively). Five hematologic serious adverse events were reported with lenalidomide maintenance (pancytopenia [n = 2], febrile neutropenia, anemia, and thrombocytopenia [n = 1 each]) and 1 with no maintenance (thrombocytopenia). Second primary malignancies occurred at rates of 1.38 and 2.19 events per patient-year in lenalidomide maintenance and no maintenance groups, respectively. Survival benefits associated with lenalidomide maintenance previously demonstrated in clinical trials were observed in this community-based Connect MM Registry.<\/jats:p>","DOI":"10.1182\/bloodadvances.2018017186","type":"journal-article","created":{"date-parts":[[2018,7,9]],"date-time":"2018-07-09T15:59:44Z","timestamp":1531151984000},"page":"1608-1615","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":32,"title":["Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM"],"prefix":"10.1182","volume":"2","author":[{"given":"Sundar","family":"Jagannath","sequence":"first","affiliation":[{"name":"Mount Sinai Hospital, New York, NY;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafat","family":"Abonour","sequence":"additional","affiliation":[{"name":"Simon Cancer Center, Indiana University, Indianapolis, IN;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian G. M.","family":"Durie","sequence":"additional","affiliation":[{"name":"Cedars-Sinai Medical Center, Los Angeles, CA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohit","family":"Narang","sequence":"additional","affiliation":[{"name":"US Oncology Research, Columbia, MD;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Howard R.","family":"Terebelo","sequence":"additional","affiliation":[{"name":"Providence Cancer Institute, Novi, MI;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina J.","family":"Gasparetto","sequence":"additional","affiliation":[{"name":"Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, NC;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen","family":"Toomey","sequence":"additional","affiliation":[{"name":"Steeplechase Cancer Center, Somerville, NJ;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James W.","family":"Hardin","sequence":"additional","affiliation":[{"name":"Arnold School of Public Health, University of South Carolina, Columbia, SC;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynne","family":"Wagner","sequence":"additional","affiliation":[{"name":"Institute for Regenerative Medicine, Wake Forest University School of Medicine, Winston-Salem, NC;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Celgene Corporation, Summit, NJ; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shankar","family":"Srinivasan","sequence":"additional","affiliation":[{"name":"Celgene Corporation, Summit, NJ; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amani","family":"Kitali","sequence":"additional","affiliation":[{"name":"Celgene Corporation, Summit, NJ; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. Dawn","family":"Flick","sequence":"additional","affiliation":[{"name":"Celgene Corporation, Summit, NJ; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Sturniolo","sequence":"additional","affiliation":[{"name":"Celgene Corporation, Summit, NJ; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert M.","family":"Rifkin","sequence":"additional","affiliation":[{"name":"Rocky Mountain Cancer Centers, US Oncology Network, Denver, CO"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2018,7,9]]},"reference":[{"issue":"suppl 1","key":"2020102815572531300_B1","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S0145-2126(12)70003-6","article-title":"Can we change the disease biology of multiple myeloma?","volume":"36","author":"Borrello","year":"2012","journal-title":"Leuk Res"},{"key":"2020102815572531300_B2","first-page":"293479","article-title":"The role of regulatory T cells and TH17 cells in multiple myeloma","volume-title":"Clin Dev Immunol","author":"Braga","year":"2012"},{"issue":"10","key":"2020102815572531300_B3","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1402888","article-title":"Autologous transplantation and maintenance therapy in multiple myeloma","volume":"371","author":"Palumbo","year":"2014","journal-title":"N Engl J Med"},{"issue":"19","key":"2020102815572531300_B4","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","article-title":"Lenalidomide maintenance after stem-cell transplantation for multiple myeloma","volume":"366","author":"Attal","year":"2012","journal-title":"N Engl J Med"},{"issue":"7","key":"2020102815572531300_B5","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.bbmt.2015.03.002","article-title":"Hematopoietic stem cell transplantation for multiple myeloma: guidelines from the American Society for Blood and Marrow Transplantation","volume":"21","author":"Shah","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"19","key":"2020102815572531300_B6","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","article-title":"Lenalidomide after stem-cell transplantation for multiple myeloma","volume":"366","author":"McCarthy","year":"2012","journal-title":"N Engl J Med"},{"issue":"22","key":"2020102815572531300_B7","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1182\/blood.V128.22.244.244","article-title":"Response adapted induction treatment improves outcomes for myeloma patients: results of the phase III myeloma XI study [abstract]","volume":"128","author":"Jackson","year":"2016","journal-title":"Blood"},{"issue":"29","key":"2020102815572531300_B8","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","article-title":"Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis","volume":"35","author":"McCarthy","year":"2017","journal-title":"J Clin Oncol"},{"issue":"9","key":"2020102815572531300_B9","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.3109\/10428194.2015.1132419","article-title":"Connect MM(R)\u2013the Multiple Myeloma Disease Registry: incidence of second primary malignancies in patients treated with lenalidomide","volume":"57","author":"Rifkin","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"2020102815572531300_B10","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.clml.2014.12.002","article-title":"Connect MM Registry: the importance of establishing baseline disease characteristics","volume":"15","author":"Rifkin","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"2020102815572531300_B11","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/ajh.24796","article-title":"Recognition of early mortality in multiple myeloma by a prediction matrix","volume":"92","author":"Terebelo","year":"2017","journal-title":"Am J Hematol"},{"issue":"18","key":"2020102815572531300_B12","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","article-title":"Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1","volume":"117","author":"Rajkumar","year":"2011","journal-title":"Blood"},{"issue":"2","key":"2020102815572531300_B13","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.cmpb.2007.07.010","article-title":"A SAS macro for estimation of direct adjusted survival curves based on a stratified Cox regression model","volume":"88","author":"Zhang","year":"2007","journal-title":"Comput Methods Programs Biomed"},{"issue":"3","key":"2020102815572531300_B14","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/leu.2012.282","article-title":"Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project","volume":"27","author":"Avet-Loiseau","year":"2013","journal-title":"Leukemia"},{"issue":"2","key":"2020102815572531300_B15","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1093\/annonc\/mdw606","article-title":"Second primary malignancies in multiple myeloma: an overview and IMWG consensus","volume":"28","author":"Musto","year":"2017","journal-title":"Ann Oncol"},{"issue":"9","key":"2020102815572531300_B16","doi-asserted-by":"crossref","first-page":"e431","DOI":"10.1016\/S2352-3026(17)30140-0","article-title":"Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial","volume":"4","author":"Holstein","year":"2017","journal-title":"Lancet Haematol"},{"issue":"2","key":"2020102815572531300_B17","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/leu.2013.247","article-title":"IMWG consensus on risk stratification in multiple myeloma","volume":"28","author":"Chng","year":"2014","journal-title":"Leukemia"}],"updated-by":[{"DOI":"10.1182\/bloodadvances.2020001494","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2020,1,29]],"date-time":"2020-01-29T00:00:00Z","timestamp":1580256000000}}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/2\/13\/1608\/1779973\/advances017186.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/2\/13\/1608\/1779973\/advances017186.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T19:57:36Z","timestamp":1603915056000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/2\/13\/1608\/15928\/Impact-of-postASCT-maintenance-therapy-on-outcomes"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,9]]},"references-count":17,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2018,7,10]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2018017186","relation":{"erratum":[{"id-type":"doi","id":"10.1182\/bloodadvances.2020001494","asserted-by":"object"}]},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,9]]}}}